MRX
Marex Group plc Ordinary Shares
There isn't enough reported data to score MRX yet.
MS
Morgan Stanley
MS's fundamentals are strong: revenue grew 16% and earnings per share grew 29%. At 15x earnings, it's trading in line with its usual 14x. Analysts expect earnings growth.
MRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| N/A | |
| N/A |
There isn't enough reported data to rate MRX's fundamentals.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
MRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | N/A | N/A |
| Fair | 14x | N/A | N/A |
| Expensive | 17x | N/A | N/A |
| Current | 18x | $71.68 | — |
Historical ranges are pointers, not guarantees.
MRX's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
MRX Forward outlook
There aren't enough analyst estimates for MRX to show an outlook.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
MRX Earnings Per Share
MRX and MS do not have enough comparable growth data to identify a winner.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS's earnings per share have climbed steadily: $12.60 over the past year, up 29% from the year before, and higher year over year for 10 quarters in a row.
MRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2B | +306% |
| Q4 2025 | $3.1B | +45% |
| Q2 2025 | $500.1M | -32% |
| Q4 2024 | $2.2B | +199% |
| Q2 2024 | $740M | -36% |
| Q4 2023 | $720.7M | +109% |
| Q2 2023 | $1.2B | +75% |
| Q4 2022 | $345.3M | -16% |
MRX has the edge over MS in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 59% | +6.1 points |
| Q4 2025 | 34% | +50 points |
| Q2 2025 | 20% | +19 points |
| Q4 2024 | 20% | +2.2 points |
| Q2 2024 | 53% | +47 points |
| Q4 2023 | -16% | -25 points |
| Q2 2023 | 0.8% | -7.5 points |
| Q4 2022 | 18% | +13 points |
MRX has the edge over MS on profitability, with a higher operating margin.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS's revenue has grown year over year for 14 quarters in a row: $20.3B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
MRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $692M | -25% |
| Q4 2025 | -$264.5M | -138% |
| Q2 2025 | $918.9M | +107% |
| Q4 2024 | $704.6M | +95% |
| Q2 2024 | $443.3M | +23% |
| Q4 2023 | $361.5M | +234% |
| Q2 2023 | $361.5M | +234% |
| Q4 2022 | $108.1M | -53% |
MRX's free cash flow was $2.1B over the past year, up 61% from the year before. Free cash flow isn't a meaningful measure for financial services companies like MRX.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
MRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -487K shares |
| 1 year | +4.7% | +3.4M shares |
| 3 years | +25% | +15M shares |
MRX has 76M diluted shares, up 4.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $125.6M |
| Q4 2025 | $200,000 |
| Q2 2025 | — |
| Q4 2024 | — |
| Q2 2024 | $19.8M |
| Q4 2023 | $1.6M |
| Q2 2023 | $1.6M |
| Q4 2022 | $4M |
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over MRX on shareholder dilution, with a more favorable share count trend.
MRX Net Leverage
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
MRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.8 | Neutral |
| Stochastic | 40.9 | Neutral |
MRX's weekly RSI is 59 (neutral) and its Stochastic is 41 (neutral).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
MRX PE vs Financial Services Sector
| Metric | MRX | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 13x | 42% above |
| PE % | 93 | 29 | 64 pts above |
MRX is trading at 18x earnings, a 42% premium to the Financial Services sector's median of 13x, though its earnings don't support one.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS has the edge over MRX on valuation relative to its sector.
MRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $69.8 | 2.6% above |
| 20 week MA | $69.1 | 3.8% above |
| 50 week MA | $55.3 | 30% above |
| 100 week MA | $45.7 | 57% above |
MRX has stronger trend alignment. MRX is above 4 of 4 weekly averages versus MS above 3 of 5.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
MRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $19.0 | $31.9 | +68% |
| 2025 | $31.9 | $39.6 | +24% |
| 2026 YTD | $39.6 | $71.7 | +81% |
MRX has the edge over MS on returns for 2026, with the stronger performance.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.